We are proud to announce the recent expansion of our portfolio of companies.
We are proud to announce the recent expansion of our portfolio of companies. We welcome two newcomers – Incephalo and NextImmune – to our family.
With all our companies, we do whatever is needed to see them succeed. From providing access to best-in-class scientific avenues to defining key milestones to de-risk the science or sharpening their overall positioning. We do this together with relevant consultants and experts and involve our partners, where they can add value. Similar to all the other members of our portfolio, Incephalo and NextImmune’s value proposition lies in developing innovative therapies to positively impact the lives of patients suffering from diseases of high unmet medical need.
InCephalo, is a preclinical stage spin-off from the University of Zurich with a compartment-locked (CLocked) technology. CLocked biologics represent the next level in precision-targeted treatments. InCephalo is positioning itself as a CLocked Fc-Fusion Cytokine and antibody company. The company’s first asset is a CLocked IL-12Fc for the treatment of recurrent glioblastoma. A pipeline of additional assets is being built in relevant disease indications such as multiple sclerosis and Parkinson’s disease.
NextImmune, is a spin-off from the Biozentrum, University of Basel. The Company focuses on the research and development of a novel class of immunosuppressive therapies for autoimmune-inflammatory diseases and organ transplantation.
We are looking forward to report more on the journeys of these two exciting companies and invite you to join us on welcoming them into this wonderful ecosystem.
Click here to see our full portfolio.